BioXcel Therapeutics, Inc.
BTAI
$1.31
$0.064.80%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 22.62% | -30.05% | -54.21% | -89.13% | -71.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.62% | -30.05% | -54.21% | -89.13% | -71.13% |
| Cost of Revenue | 1,921.43% | -96.15% | -99.06% | 72.58% | -82.50% |
| Gross Profit | -150.00% | 148.07% | 109.10% | -98.75% | -69.32% |
| SG&A Expenses | 26.18% | -7.06% | -29.96% | -40.65% | -57.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.58% | -2.67% | 1.28% | -8.96% | -58.51% |
| Operating Income | -1.23% | 1.71% | -2.14% | 3.58% | 58.20% |
| Income Before Tax | -74.95% | -15.53% | -126.45% | -131.20% | 72.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -74.95% | -15.53% | -126.45% | -131.20% | 72.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.95% | -15.53% | -126.45% | -131.20% | 72.92% |
| EBIT | -1.23% | 1.71% | -2.14% | 3.58% | 58.20% |
| EBITDA | -1.42% | 1.69% | -2.17% | 3.58% | 58.38% |
| EPS Basic | 64.12% | 83.94% | 57.74% | 25.83% | 89.20% |
| Normalized Basic EPS | 64.12% | 83.89% | 52.62% | 17.30% | 89.20% |
| EPS Diluted | 64.12% | 83.94% | 57.74% | 25.83% | 89.20% |
| Normalized Diluted EPS | 64.12% | 83.89% | 52.62% | 17.30% | 89.20% |
| Average Basic Shares Outstanding | 387.61% | 619.18% | 435.90% | 211.72% | 150.60% |
| Average Diluted Shares Outstanding | 387.61% | 619.18% | 435.90% | 211.72% | 150.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |